Ge Long Hui·2025-09-26 10:57Core Viewpoint - Fosun Pharma (02196.HK) announced plans to divest 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1] Group 1: Transaction Details - Fosun Pharma's subsidiary, Fosun Pharma Industry, plans to invest RMB 54.6 million as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance, expecting to hold 9.98% of the fund's assets after full fundraising [1] - Following the establishment of the special fund and fulfillment of agreed conditions, Fosun Pharma Industry intends to transfer its 100% equity in Shanghai Clone and related debts for no more than RMB 1.256 billion to the special fund or its controlled entities [1] - After the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property as an operating site, with no significant impact on daily operations expected [1] Group 2: Use of Proceeds - Proceeds from the transfer will be allocated to the continuous investment in the group's innovative drug business [1]